CellCentric strengthens Board and executive leadership with appointments of Paolo Pucci and Jason Cavalier
Appointments add extensive public-company governance, capital markets, financing and transaction experience as CellCentric prepares for its next phase of growth CellCentric, a clinical-stage biopharmaceutical company developing inobrodib, an oral, first-in-class p300/CBP inhibitor, for the treatment of multiple myeloma and other cancers, today announced the appointment of Paolo Pucci as a Non-Executive Director and Jason Cavalier as Chief Financial Officer. The […]
CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma
Cambridge, UK and Boston, MA, May 6, 2026 – CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the completion of an oversubscribed $220 million Series D financing. The financing was led by specialist investor Venrock Healthcare Capital Partners, with participation from a […]
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma
– Enrollment underway in UK and U.S. for initial registration-supporting study; first patient dosed at The Royal Marsden NHS Foundation Trust in London – – InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or anti-BCMA therapy – Cambridge, […]
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
Cambridge, UK and Boston, MA, 7 Dec 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced new data from dose optimization cohorts of its Phase 2 clinical trial of inobrodib in combination with pomalidomide (pom) and dexamethasone (dex; InoPd) in […]
CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Cambridge, UK and Boston, MA, 3 Nov 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced that it will deliver a poster presentation on its novel drug, inobrodib, at the 67th Annual American Society of Hematology (ASH) Meeting and Exposition, taking […]
CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma
Cambridge, UK and Boston, MA, 09 September – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced completion of patient enrollment in the randomized dose optimization portion of its Phase 1/2 clinical trial evaluating inobrodib in combination with standard doses of pomalidomide and […]
CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma
Cambridge, United Kingdom and Boston, Massachusetts, September 3rd, 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced that it has initiated dosing in new cohorts evaluating inobrodib in combination with B-cell maturation antigen (BCMA) directed CD3 T-cell engagers. The ongoing Phase […]
CellCentric to Participate in Upcoming Investor Conferences
Cambridge, UK and Boston, MA – August 5th, 2025 – CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences. These events provide an opportunity to engage with the investment community and highlight the […]
CellCentric secures $120 million investment to advance inobrodib for treating multiple myeloma
Cambridge, UK and Boston, MA – May 19, 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma, today announced the completion of a $120 million Series C funding round. The financing was co-led by RA Capital Management and new investor Forbion, […]
CellCentric Expands US Presence with New Office in Boston
Boston, MA – April 2, 2025 – CellCentric, a clinical stage biotechnology company, today announces the opening of a new office in Boston, Massachusetts marking a significant step in expanding its presence in the United States. This will increase the company’s drug development capacity, progressing its novel drug treating multiple myeloma, inobrodib. Located in Burlington, […]